# US 2024/0002825 A1 · Ph20 polypeptide variants, formulations and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002825 A1
- Document ID: US20240002825A1
- Status: Published application
- Kind: A1
- Application number: 18/340,482
- Filed: 2023-06-23
- Published: 2024-01-04
- Earliest claimed: 2011-12-30
- Assignees: Halozyme, Inc.
- Applicants: Halozyme,Inc.
- Inventors: Ge WEI; H. Michael Shepard; Qiping Zhao; Robert James Connor
- Web page: https://patentgrep.com/patent/US20240002825A1

## CPC

- C12N 9/2474: {Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 38/28: Insulins
- A61K 38/47: acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/47: from mammals
- C12Q 1/34: involving hydrolase
- C12Y 302/01035: Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- G01N 2333/926: acting on alpha -1, 4-glucosidic bonds, e.g. hyaluronidase, invertase, amylase
- G01N 2333/928: acting on alpha -1, 4-glucosidic bonds, e.g. hyaluronidase, invertase, amylase
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Y: ENZYMES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof.

## Claims

### Claim 1

A modified PH20 polypeptide comprising an amino acid sequence, wherein:
(a) at least 95% of the residues of the amino acid sequence of the modified PH20 polypeptide are identical to the residues in an amino acid sequence selected from the group consisting of SEQ ID NOs: 3 and 32-66 when the sequence of the modified PH20 polypeptide is aligned at positions corresponding to the sequence selected from the group consisting of SEQ ID NOs: 3 and 32-66 to maximize identical residues, and wherein terminal gaps are treated as non-identical; and
(b) the amino acid sequence of the modified PH20 polypeptide comprises an amino acid modification at a position corresponding to position 313 with reference to amino acid positions set forth in SEQ ID NO: 3; and
(c) the modification at position 313 is a replacement selected from among A, H, K, L, P, R, and Y.

### Claim 2 (depends on 1)

The modified PH20 polypeptide of claim 1, wherein the amino acid modification is at a position corresponding to position 313 with reference to amino acid positions set forth in SEQ ID NO: 3 is K.

### Claim 3 (depends on 2)

The modified PH20 polypeptide of claim 2, wherein at least 96% of the residues of the amino acid sequence of the modified PH20 polypeptide are identical to the residues in an amino acid sequence set forth in SEQ ID NO:35.

### Claim 4 (depends on 2)

The modified PH20 polypeptide of claim 2, wherein at least 95% of the residues of the amino acid sequence of the modified PH20 polypeptide are identical to the residues in an amino acid sequence set forth in SEQ ID NO:32.

### Claim 5 (depends on 1)

The modified PH20 polypeptide of claim 1, wherein the modified PH20 polypeptide exhibits increased hyaluronidase activity compared to the hyaluronidase activity of the polypeptide set forth in SEQ ID NO: 3, measured under identical conditions.

### Claim 6 (depends on 1)

The modified PH20 polypeptide of claim 1, wherein the hyaluronidase activity of the modified PH20 polypeptide is at least 120% of the hyaluronidase activity of the PH20 polypeptide of SEQ ID NO: 3, measured under identical conditions.

### Claim 7 (depends on 1)

The modified PH20 polypeptide of claim 1 that is a soluble PH20 polypeptide.

### Claim 8 (depends on 1)

The modified PH20 polypeptide of claim 1 that comprises one or more modifications of the polypeptide selected from among glycosylation, sialylation, albumination, farnesylation, carboxylation, hydroxylation, and phosphorylation.

### Claim 9 (depends on 8)

The modified PH20 polypeptide of claim 8 that is glycosylated.

### Claim 10 (depends on 9)

The modified PH20 polypeptide of claim 9, wherein the polypeptide is a glycoprotein that comprises an N-acetylglucosamine moiety linked to each of at least three asparagine (N) residues.

### Claim 11 (depends on 1)

A nucleic acid encoding the modified PH20 polypeptide of claim 1.

### Claim 12 (depends on 11)

A recombinant expression vector, comprising the nucleic acid of claim 11.

### Claim 13 (depends on 12)

A host cell, comprising the vector of claim 12.

### Claim 14 (depends on 1)

A pharmaceutical composition, comprising the modified PH20 polypeptide of claim 1.

### Claim 15 (depends on 14)

The pharmaceutical composition of claim 14, further comprising a therapeutically active agent, wherein the therapeutically active agent is formulated in the same composition or is formulated in a separate composition.

### Claim 16 (depends on 15)

A pharmaceutical composition of claim 15, wherein the therapeutically active agent is a polypeptide, a protein, a nucleic acid, a drug, a small molecule, or an organic molecule.

### Claim 17 (depends on 16)

The pharmaceutical composition of claim 16, wherein the therapeutically active agent is an antibody.

### Claim 18 (depends on 16)

The pharmaceutical composition of claim 16, wherein the therapeutically active agent is a small molecule drug.

### Claim 19 (depends on 15)

A method for administering a therapeutically active agent, comprising providing a pharmaceutical composition of claim 15, and parenterally administering the composition or compositions.

### Claim 20 (depends on 19)

The method of claim 19, wherein said parenterally administering is subcutaneously administering.

### Claim 21 (depends on 15)

A method for treating cancer, comprising administering a pharmaceutical composition of claim 15 to a subject in need thereof.

### Claim 22 (depends on 21)

The method of claim 21, wherein said administering is to a subject receiving treatment with an anticancer drug.

### Claim 23

A method for manufacture of a protein, comprising preparing a plasmid DNA containing a cDNA encoding the protein comprising an amino acid sequence, wherein:
(a) the protein is a modified PH20 polypeptide;
(b) at least 95% of the residues of the amino acid sequence of the encoded modified PH20 polypeptide, excluding any signal sequence, are identical to the residues an amino acid sequence selected from the group consisting of SEQ ID NOs: 3 and 32-66 when the sequence of the modified PH20 polypeptide is aligned at positions corresponding to the sequence selected from the group consisting of SEQ ID NOs: 3 and 32-66 to maximize identical residues, and wherein terminal gaps are treated as non-identical; and
(c) the amino acid sequence of the modified PH20 polypeptide comprises an amino acid modification at a position corresponding to position 313 with reference to amino acid positions set forth in SEQ ID NO: 3, and the modification at position 313 is selected from among A, H, K, L, P, R, and Y; and
wherein the method comprises:
transfecting the plasmid into a host cell;
culturing the cell under conditions for expression of the cDNA as a protein; and
harvesting the protein from the culture.
